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AbstrACt
Introduction and objectives Macrolides have been 
associated with proarrhythmic properties, but the evidence 
is conflicting. We evaluated the risk of out-of-hospital 
cardiac arrest (OHCA) associated with specific macrolides 
in a retrospective study. Associations between specific 
macrolides and OHCA were examined by conditional 
logistic regression analyses in case-crossover and case–
time–control models, using penicillin-V treatment as the 
comparative reference. From nationwide registries, we 
identified all OHCAs in Denmark from 2001 to 2010 and 
use of antibiotics.
Ethics The present study was approved by the Danish 
Data Protection Agency (Danish Data Protection Agency  
( ref. no. 2007-58-0015, local  ref. no. GEH-2014-017,  
( I- Suite. nr. 02 735)).
Participants We identified 29 111 patients with an OHCA. 
Of these, 514 were in macrolide treatment ≤7 days before 
OHCA and 1237 in penicillin-V treatment.
results In the case-crossover analyses, overall macrolide 
use was not associated with OHCA with penicillin V 
as negative comparative reference (OR=0.90; 95% CI 
0.73 to 1.10). Compared with penicillin-V treatment, 
specific macrolides were not associated with increased 
risk of OHCA: roxithromycin (OR=0.97; 95% CI 0.74 to 
1.26), erythromycin (OR=0.68; 95% CI 0.44 to 1.06), 
clarithromycin (OR=0.95; 95% CI 0.61 to 1.48) and 
azithromycin (OR=0.85; 95% CI 0.57 to 1.27). Similar 
results were obtained using case–time–control models: 
overall macrolide use (OR=0.81; 95% CI 0.62 to 1.06) 
and specific macrolides (roxithromycin (OR=0.70; 95% 
CI 0.49 to 1.00), erythromycin (OR=0.67; 95% CI 0.38 to 
1.18), clarithromycin (OR=0.75; 95% CI 0.41 to 1.39) or 
azithromycin (OR=1.17; 95% CI 0.70 to 1.95)).
Conclusion The risk of OHCA during treatment with 
macrolides was similar to that of penicillin V, suggesting no 
additional risk of OHCA associated with macrolides.
IntroduCtIon 
Macrolides are commonly used to treat a 
range of infections including upper and lower 
respiratory tract infections and sexually trans-
mitted diseases. Moreover, macrolides are 
often the drug of choice in patients known 
to be penicillin intolerant.1–4 However, a 
known possible adverse drug reaction related 
to macrolide treatment is prolongation of 
the QT interval, which increase the risk of 
torsades de pointes (TdP) ventricular tachy-
cardia, a potentially fatal arrhythmia.2 3 5 6 
To date, the cardiac risks associated 
with specific macrolides (ie, roxithro-
mycin, erythromycin, clarithromycin and 
azithromycin) have been evaluated in 
several studies, but the findings have been 
conflicting. As such, use of erythromycin 
has been associated with case reports of 
TdP and increased risk of sudden cardiac 
death (SCD).7 Azithromycin use, as 
compared with no treatment or treatment 
with a phenoxymethylpenicillin (ie, peni-
cillin V), was previously associated with 
increased cardiovascular mortality while 
no association was found for use of clari-
thromycin.2 8 9 Furthermore, azithromycin 
strengths and limitations of this study
 ► Although the proarrhythmic properties of macrolide 
treatment may have prolonged the QT interval 
prior to the out-of-hospital cardiac arrest (OHCA), 
we are not able to prove such causation given the 
observational nature of the study.
 ► The infrequency of OHCA as outcome of this 
treatment limited the final study cohort and may 
have influenced our findings.
 ► We cannot rule out that incorrect diagnosing can 
lead to OHCA and a misinterpreted association with 
use of antibiotic.
 ► Data on specific infections, for which the drugs were 
prescribed, were not available for this study.
 ► Our current study holds the strength of enrolling 
members of the general population from a nationwide 
database containing all patients suffering from an 
OHCA and data on all patient usage of antibiotics.
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was typically found to be dispensed for 5 days and the 
increase in mortality and arrhythmia risks were highest 
within these first 5 days.2 9 Still, the absolute excess risk 
compared with a penicillin V varied and appropriate 
questions were raised about whether the associations 
could be generalised to include populations with low 
baseline risk of cardiovascular disease.8–10 In a Danish 
study, by Svanstrøm et al, use of clarithromycin was 
observed to be associated with a significantly increased 
risk of cardiac death compared with use of penicillin V 
among Danish adults, 40–74 years of age with no known 
serious disease.5 Yet, no increased risk was found for 
use of roxithromycin nor azithromycin in populations 
of young and middle-aged adults, 18–70 years of age.5 8
The increased risk of cardiovascular death has addi-
tionally been found to be higher among adults with 
a high baseline risk for cardiovascular disease and 
suggests that pre-existing risk factors play an important 
role.2 3 5 8 9 As a consequence, the Food and Drug 
Administration issued a drug safety communication 
warning the public that azithromycin could potentially 
lead to irregular heart rhythm and caution should be 
shown for individuals at risk for drug-induced ventric-
ular arrhythmias.4
Table 1 Characteristics for patients receiving penicillin V and macrolides
Penicillin V All macrolides P value
N 1237 514
Age, years (IQR) 68.6 (58.4–80.5) 71.3 (60.8–80.4) 0.73
Male (%) 764 (61.8) 268 (52.1) <0.001
Income group (%)
  0 (lowest income quintile) 124 (10.0) 60 (11.7)
  1 322 (26.0) 131 (25.5)
  2 369 (29.8) 155 (30.2) 0.71
  3 231 (18.7) 100 (19.5)
  4 (highest income quintile) 189 (15.3) 68 (13.2)
Comorbidity (%)
  Diabetes 144 (11.6) 74 (14.4) 0.11
  Peripheral vascular disease 50 (4.0) 24 (4.7) 0.55
  Previous MI 97 (7.8) 47 (9.1) 0.37
  Ischaemic heart disease 177 (14.3) 61 (11.9) 0.17
  Heart failure 175 (14.2) 70 (13.6) 0.77
  Atrial fibrillation 126 (10.2) 45 (8.8) 0.36
  COPD 201 (16.3) 121 (23.5) <0.001
  Cancer 132 (10.7) 43 (8.4) 0.14
  Depression 33 (2.7) 15 (2.9) 0.77
  Any psychiatric disease 164 (13.3) 57 (11.1) 0.21
Charlson score (IQR) 0 (0–2) 1 (0–2) 0.08
Concomitant pharmacotherapy (%)
  Lipid-lowering drugs 127 (10.3) 69 (13.4) 0.06
  Loop diuretics 342 (27.7) 165 (32.1) 0.06
  Beta-blockers 202 (16.3) 96 (18.7) 0.23
  ACE inhibitors 245 (19.8) 122 (23.7) 0.07
  Vitamin K antagonists 71 (5.7) 29 (5.6) 0.94
  Antiplatelets 20 (1.6) 11 (2.1) 0.45
  Antipsychotics 125 (10.1) 53 (10.3) 0.90
  Antidepressants 243 (19.6) 109 (21.2) 0.46
  Anxiolytics 365 (29.5) 155 (30.2) 0.79
Dichotomous variables reported in absolute numbers and percentages.
Continuous variables reported in medians and IQR.
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
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Overall, the conflicting results between studies 
on the effects of macrolides underscore the need to 
clarify the risk associated with macrolides in general. 
Denmark provides the optimal setting for an investi-
gation, due to the nationwide databases on hospital 
contacts and prescription of medicine. Our purpose 
with the retrospective study was therefore to investi-
gate the risk of OHCA in patients prescribed a macro-
lide (roxithromycin, erythromycin, clarithromycin or 
azithromycin) using conditional logistic regression in 
case-crossover analyses with penicillin-V treatment as 
comparative reference, since penicillin holds similar 
indications as macrolides, but with no known cardiac 
risks.5 11
MEthods
study population
All OHCAs in Denmark from 2001 to 2010 that resulted 
in resuscitative efforts by bystanders (with activation 
of the emergency medical services (EMS) system) or 
EMS personnel according to the Danish Cardiac Arrest 
Register were included in the present study. We included 
all patients with OHCA who on 1 January 1997 were ≥10 
Table 2 Characteristics of out-of-hospital cardiac arrest patients in treatment with a specific macrolide ≤7 days before the 
time of event
Azithromycin Clarithromycin Erythromycin Roxithromycin P value*
N (%) 82 (16.0) 88 (17.1) 82 (16.0) 262 (51.0)
Age, years (IQR) 69.0 (59.6–77.4) 72.1 (64.4–80.4) 68.6 (52.5–77.8) 72.5 (61.4–81.6) 0.03
Male (%) 46 (56.1) 44 (50.0) 37 (45.1) 141 (53.8) 0.46
Income group (%)
  0 (lowest income quintile) 10 (12.2) 8 (9.1) 14 (17.1) 28 (10.7)
  1 21 (25.6) 26 (29.6) 18 (22.0) 66 (25.2)
  2 23 (28.1) 28 (31.8) 27 (32.9) 77 (29.4) 0.15
  3 10 (12.2) 13 (14.8) 14 (17.1) 63 (24.1)
  4 (highest income quintile) 18 (22.0) 13 (14.8) 9 (11.0) 28 (10.6)
Comorbidity (%)
  Diabetes 19 (23.2) 11 (12.5) 11 (13.4) 33 (12.6) 0.11
  Peripheral vascular disease 3 (3.7) 3 (3.4) 3 (3.7) 15 (5.7) 0.83
  Previous MI 5 (6.1) 13 (14.8) 4 (4.9) 25 (9.5) 0.12
  Ischaemic heart disease 8 (9.8) 16 (18.2) 7 (8.5) 30 (11.5) 0.20
  Heart failure 13 (15.9) 17 (19.3) 10 (12.2) 30 (11.5) 0.27
  Atrial fibrillation 6 (7.3) 8 (9.1) 5 (6.1) 26 (9.9) 0.76
  COPD 24 (29.3) 20 (23.6) 15 (18.3) 62 (23.7) 0.43
  Cancer 4 (4.9) 11 (12.5) 7 (8.5) 21 (8.0) 0.36
  Depression 5 (6.1) 5 (5.7) 1 (1.2) 4 (1.5) 0.04
  Any psychiatric disease 13 (15.9) 12 (13.6) 10 (12.2) 22 (8.4) 0.21
  Charlson score (IQR) 1 (0–2) 1 (0–2) 0 (0–1) 1 (0–2) 0.16
Concomitant pharmacotherapy (%)
  Lipid-lowering drugs 13 (15.9) 10 (11.4) 9 (11.0) 37 (14.1) 0.74
  Loop diuretics 30 (36.6) 34 (38.6) 21 (25.6) 80 (30.5) 0.23
  Beta-blockers 17 (20.7) 19 (21.6) 16 (19.5) 45 (16.8) 0.71
  ACE inhibitors 22 (26.8) 28 (31.8) 14 (17.1) 58 (22.1) 0.11
  Vitamin K antagonists 5 (6.1) 3 (3.4) 2 (2.4) 19 (7.3) 0.33
  Antiplatelets 0 (0.0) 1 (1.1) 1 (1.2) 9 (3.4) 0.28
  Antipsychotics 12 (14.6) 10 (11.4) 10 (12.2) 21 (8.0) 0.31
  Antidepressants 17 (20.7) 20 (22.7) 11 (13.4) 61 (23.3) 0.29
  Anxiolytics 22 (26.8) 30 (34.1) 21 (25.6) 82 (31.3) 0.56
Dichotomous variables given in absolute numbers and percentages.
Continuous variables given in medians and IQR.
*P value for differences between roxithromycin, erythromycin, clarithromycin and azithromycin. 
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
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years old, as done previously.12 13 Patients with obvious 
signs of death (eg, trauma) or patients where no resus-
citative efforts were performed by bystanders or EMS 
personnel were not included in the Danish Cardiac 
Arrest Registry. Notably, EMS personnel (nationwide) are 
required to fill out and submit a case report form to the 
Danish Cardiac Arrest Registry for every OHCA including 
information on date, time and occurrence of OHCA that 
ensures a valid and accurate registry.14
databases
All Danish citizens are assigned a unique and permanent 
civil registration number that enables individual-lev-
el-linkage of nationwide registers. For the present study, 
we used information from the Danish National Patient 
Registry, the Danish Registry of Medicinal Product Statis-
tics, the National Danish Register of Causes of Death 
and the Danish Integrated Database for Labour Market 
Research.
Included in the Danish National Patient Registry is 
information on every hospital admission and discharge 
(ie, one primary diagnosis and if appropriate two or more 
secondary diagnoses) according to the International Clas-
sification of Diseases 10th revision (ICD-10).15
Since 1995, detailed information on all dispensed 
drug prescriptions from Danish pharmacies have 
been registered in the Danish Registry of Medicinal 
Product Statistics using the Anatomical Therapeutic 
Chemical (ATC) system.16 The register is valid and 
accurate as all Danish pharmacies are obliged by law to 
register prescriptions due to the partial reimbursement 
of drug expenses by the government-financed health-
care system.16
The National Danish Register of Causes of Death holds 
information on the primary as well as contributing causes 
of death.
Patient comorbidity and concomitant pharmacotherapy
Patient comorbidity was defined through the Danish 
National Patient Registry using primary or secondary 
hospital discharge diagnoses (up to 5 years before the 
date of OHCA) for the following diseases specified in 
the Charlson Comorbidity Index and adapted for use 
with ICD-10 classification system: atrial fibrillation, cere-
bral vascular disease, chronic obstructive pulmonary 
disease, heart failure, ischaemic heart disease, malig-
nancy, myocardial infarction and peripheral vascular 
disease.17–19 Diabetes was defined by a redeemed prescrip-
tion for any glucose-lowering medication (ATC:A10; oral 
or insulin) ≤180 days before the time of OHCA according 
to the Danish Register of Medicinal Product Statistics. 
A history of any psychiatric illness and depression was 
defined by discharge diagnoses and patients with suicide 
were defined by primary causes of death. Socioeconomic 
status was defined by averaging annual income within 
5 years.
Figure 1 Trends in macrolide and penicillin-V drug usage 7 days before event among individuals who experienced an out-of-
hospital cardiac arrest (2001–2010).
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Concurrent pharmacotherapy was defined by a claimed 
prescription ≤90 days before the time of OHCA for the 
following drugs (ATC-codes): ACE inhibitors (A09A), 
vitamin K-antagonists (B01AA), antiplatelets (B01AC), 
loop diuretics (C03C), beta-blockers (C07), choles-
terol-lowering agents (C10), sedatives and anxiolytics 
(N05B and N05C), and antidepressants (N06A).
Antibiotic pharmacotherapy
We identified the most commonly used macrolides and 
penicillin V among all OHCA cases and age-matched and 
gender-matched controls from 2001 to 2010 (ATC-code): 
roxithromycin (J01FA06), erythromycin (J01FA01), 
clarithromycin (J01FA09), azithromycin (J01FA10) and 
phenoxymethylpenicillin (J01CE02). For each of the 
above-mentioned antibiotics, we determined treatment 
duration by dividing the number of tablets in the prescrip-
tion of interest with the estimated daily dosage, as defined 
by current national guidelines.12 13 20 21
statistical analysis
We compared categorical variables for penicillin V and 
macrolides users with the χ2 test or Fishers exact where 
appropriate. Continuous variables were compared with 
the Kruskall-Wallis test. We used the Cochran-Armitage 
trend test to evaluate trends in antibiotic treatment.
In our primary analysis, we examined the risk of OHCA 
associated with specific macrolides using conditional 
logistic regression in case-crossover analyses and with 
penicillin-V treatment as comparative references.22 In 
brief, the case-crossover design is based on the principles 
of each individual serving as his or her own control in 
different time periods. By using each individual as his or 
her own control, the method is able to adjust for time-in-
variant confounders including chronic comorbidities (eg, 
obesity, hypertension and smoking) as well as concomi-
tant pharmacotherapy (eg, statin and beta-blockers) and 
is suitable for studying transient effects on the risk of 
acute events.22
The case-crossover design only uses patients with discor-
dant exposure histories, so that patients treated in the case 
period support an OR >1. Conversely, patients treated in 
the control period support an OR <1. Hence, patients 
with concordant exposure histories do not contribute to 
the case-crossover analysis. For the present case-crossover 
study design, we used one reference period which means 
that the assumption of conditional independence of 
exposure at different time-points is not violated.23–25 We 
defined the case period as 0–7 days before OHCA and the 
reference period as 14–21 days before OHCA. A washout 
period was defined as 7–14 days before OHCA to elimi-
nate possible carry-over effects.
In addition to the case-crossover method, we also 
performed a secondary analysis using the case–time–
control design in order to adjust for time trends in the 
general prescribing patterns which may otherwise lead to 
biased results.23 24 The case–time–control design, extend 
the case-crossover study design using a control group to 
account for changes in prescribing patterns not related to 
the outcome of interest that may otherwise lead to biased 
results.
For the case–time–control analysis, we used the Danish 
National Patient Registry, to match each OHCA case 
with four controls on age and gender using the greedy 
matching algorithm.12 13 The control population was 
Figure 2 Macrolide treatment and risk of out-of-hospital cardiac arrest using penicillin V as the comparative reference 
according to the case-crossover analysis. Presented are OR from the conditional logistic regression analysis in case-crossover 
models (95%CI). *OHCA cases contributing to the analysis were those having a discordant drug exposure history in the case 
and control periods. OHCA, out-of-hospital cardiac arrest. 
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identified in order to account for prescribing changes 
in the general population.26 Notably, exposure for each 
control was determined using the same date of OHCA as 
the matched case. A two-sided P value <0.05 was consid-
ered statistically significant. All analyses were performed 
using SAS, V.9.4 (SAS Institute).
other analysis
We tested the robustness of our study findings in multiple 
sensitivity analyses. While the main case-crossover anal-
ysis used 7-day treatment periods, we also performed 
additional case-crossover and case–time–control analyses 
with 5, 10, 14 and 21 days treatment periods. In order to 
eliminate the potential bias introduced by acute deterio-
ration in patient health before OHCA, we repeated our 
main analysis while excluding patients who had been 
admitted to hospital 14 days and 365 days before the time 
of OHCA. Separate analyses excluding patients with a 
cancer diagnosis ≤5 years before the time of OHCA were 
also performed. Moreover, we also performed additional 
analyses where we only included patients with an OHCA 
of cardiac origin according to the Utstein criteria (defini-
tions of how to report cardiac arrest data).14 Patients >18 
years old and patients with no evidence of substance 
abuse were also tested separately as were patients with no 
evidence of attempted suicide.
rEsults
From 2001 to 2010, we identified a total of 29 111 patients 
with an OHCA according to the Danish Cardiac Arrest 
Register. Of these, we identified 514 (0.02%) and 1237 
(0.04%) patients in treatment with a macrolide or peni-
cillin V ≤7 days before the time of OHCA, respectively; 
patient characteristics are listed in table 1. Overall, few 
differences in patients’ characteristics were identified 
between macrolide or penicillin-V users. Compared 
with penicillin V, OHCA patients in treatment with a 
macrolide were less likely to be men (61.8% vs 52.1%, 
respectively; P<0.001), but more likely to have chronic 
obstructive pulmonary disease (COPD) (16.3% vs 23.5%, 
respectively; P<0.001, table 1).
Among 514 patients with OHCA in treatment with a 
macrolide at the time of OHCA, we identified a total of 
262 with roxithromycin (51.0%), 82 with erythromycin 
(16.0%), 88 with clarithromycin (17.1%) and 82 in treat-
ment with azithromycin (16.0%). Characteristics for 
patients with OHCA in treatment with a specific macro-
lide at the time of event are listed in table 2. Although 
the diagnosis of depression differed according to type of 
macrolide used (P=0.04), no other significant baseline 
differences were identified across groups of macrolide 
users (P>0.05, table 2).
Overall, the use of macrolides 7 days before OHCA 
increased from 1.1% in 2001 to 1.8% in 2010 (trend; 
P<0.001) (figure 1). Similarly, macrolide use among 
the age-matched and gender-matched controls also 
increased from 0.4% in 2001 to 0.8% in 2010 (trend; 
P<0.001) (online supplementary figure 1). No signifi-
cant change in penicillin-V-prescribing patterns among 
OHCA cases from 2001 to 2010 was identified (3.2% 
and 3.8%, respectively; trend; P=0.09). Among the 
age-matched and gender-matched controls, use of peni-
cillin V decreased from 2001 to 2010 (2.1% and 1.5%, 
respectively; trend; P<0.001) (online supplementary 
figure 1).
Figure 3 Macrolide treatment and risk of out-of-hospital cardiac arrest using penicillin V as the comparative reference 
according to the according to case–time–crossover analysis. Presented are OR from the conditional logistic regression analysis 
in case–time–control models (95%CI). *OHCA cases contributing to the analysis were those having a discordant drug exposure 
history in the case and control periods. OHCA, out-of-hospital cardiac arrest.
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Case-crossover analysis
According to our main case-crossover analysis, risk of 
OHCA associated with overall macrolide use was compa-
rable with that of penicillin V (OR=0.90; 95% CI 0.73 
to 1.10) (figure 2). Similarly, non-different associations 
with OHCA with specific macrolides compared with 
penicillin V was identified for: roxithromycin (OR=0.97; 
95% CI 0.74 to 1.26), erythromycin (OR=0.68; 95% CI 
0.44 to 1.06), clarithromycin (OR=0.95; 95% CI 0.61 to 
1.48) and azithromycin (OR=0.85; 95% CI 0.57 to 1.27) 
(figure 2).
Listed in the online supplementary table 1 are the 
detailed specifications of exposure to antibiotic treatment 
by case and control periods. In the online supplementary 
figure 2 are shown macrolide and penicillin-V treatment 
and the independent associations with OHCA according 
to the case-crossover analysis.
Case–time–control analysis
Overall, the case–time–control analyses were in accor-
dance with the results from the main case-crossover 
analysis (figure 3). Thus, the association suggested lower 
OR for treatment with overall macrolide use (OR=0.81; 
95% CI 0.62 to 1.06) as well as for treatment with specific 
macrolides (roxithromycin; OR=0.70; 95% CI 0.49 to 
1.00), erythromycin (OR=0.67; 95% CI 0.38 to 1.18), clar-
ithromycin (OR=0.75; 95% CI 0.41 to 1.39) or azithro-
mycin (OR=1.17; 95% CI 0.70 to 1.95) (figure 2).
In the online supplementary figure 3, we present macro-
lide and penicillin-V treatment and the independent risk 
of OHCA according to the case–time–control analysis.
sensitivity analysis
Several additional case-crossover and case–time–control 
analyses were also performed to examine the robustness 
of our findings. In all instances, the case-crossover and 
the case–time–control analyses were congruent. First, 
we excluded patients with a hospital admission 14 days 
before the time of event that yielded similar estimates 
as the main case-crossover analysis using penicillin V as 
the comparative reference (roxithromycin (OR=0.71; 
95% CI 0.48 to 1.05), erythromycin (OR=0.75; 95% CI 
0.41 to 1.37), clarithromycin (OR=0.77; 95% CI 0.39 to 
1.49) and azithromycin (OR=1.11; 95% CI 0.65 to 1.87)).
Similar findings were made when we excluded patients 
with a hospital admission 365 days before the time of 
event (data not shown). Second, excluding patients with 
a non-cardiac aetiology in accordance with the Utstein 
criteria did also not influence our findings from the 
case-crossover analysis compared with penicillin V for 
roxithromycin (OR=1.04; 95% CI 0.75 to 1.46), eryth-
romycin (OR=0.61; 95% CI 0.35 to 1.06), clarithro-
mycin (OR=0.87; 95% CI 0.52 to 1.46) and azithromycin 
(OR=0.88; 95% CI 0.54 to 1.44).
Third, we excluded patients with cancer, but no change 
in association was identified (data not shown). Fourth, 
additional case-crossover and case–time–control anal-
yses with 5, 10, 14 and 21 days treatment periods were 
performed and did not change the identified associations 
from the main analysis (data not shown).
We were underpowered to evaluate a clinical mean-
ingful dose–response association between high-dose 
versus low-dose macrolide and OHCA.
dIsCussIon
In this nationwide study of OHCAs in Denmark, we 
found that the associated risk of OHCA was compa-
rable between overall and specific macrolide use and 
use of penicillin V. Furthermore, we found lower ORs 
for treatment with specific macrolide use (ie, roxi-
thromycin, erythromycin, clarithromycin and azith-
romycin). Hence, we are not able to show that use 
of macrolides was independently associated with an 
increased risk of OHCA when compared with peni-
cillin V. Due to inconsistency between the estimated 
risks of SCD during macrolide treatment, a question 
has been raised if the risks previously identified apply to 
the elderly or patients at risk of cardiovascular disease 
only. As an example, results from Svanström et al, using 
data from Denmark, found that azithromycin use was 
not associated with an increased risk of cardiovascular 
death (mean age, 39.5 to 42 years).10 These finding 
disagreed with those by Rao et al and Ray et al, who inves-
tigated somewhat older populations (mean age, 49 and 
56.8 years, respectively).2 9 Despite that our population 
was somewhat older than the prior studies (71.3 years 
among macrolide treated patients and 70.8 years among 
patients treated with penicillin V, table 1), we were not 
able to specifically link the usage of any macrolides to 
OHCA compared with use of penicillin V. Our results 
conflict, in part, with the previously published studies 
on adverse effects of macrolides; we did not find the 
past observed increased risks of cardiovascular mortality 
associated with macrolides and only azithromycin 
was found to have a higher point estimate compared 
with penicillin V (online supplementary figure 2).8 10 
Inherent to the statistical study design, we were able 
to adjust for time-invariant confounders by including 
chronic comorbidities and concomitant pharmaco-
therapy in the statistical analyses and also performed 
additional sensitivity analyses to eliminate bias by 
acute deterioration in patient health. The majorities of 
previous studies have been evaluations or examinations 
of national cohorts with cardiac arrhythmia or mortality 
as primary outcomes.2 5 9 10 Nonetheless, Chou et al did 
find a higher risk of cardiac arrhythmia in patients 
receiving azithromycin compared with patient receiving 
amoxicillin–clavulanate.8 However, they also found the 
risk of cardiovascular mortality to be higher among 
amoxicillin–clavulanate users than among non-users.8 
This could imply that the risks of OHCA may be due 
to underlying infection, suggesting that the compar-
ison of antibiotic users and non-users was susceptible to 
confounding by indication.8 In Denmark, and as stated 
by international guidelines, amoxicillin–clavulanate or 
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ciprofloxacin are used for more severe lower respira-
tory infections and occasionally as first-line treatment 
for pneumonia in patients with COPD.2 27 Hence, it is 
possible that patients with high-risk comorbidities or 
more severe infections may be given a broad-spectrum 
antibiotic and this could bias the estimated risk for 
OHCA. We found that a significantly higher percentage 
of patients in the macrolide group were diagnosed with 
COPD. However, this did not result in an increased OR 
compared with the penicillin-V group, as previously 
mentioned, which could have been expected since 
COPD has been associated with OHCA.28 29
In Denmark, the preferred macrolide for respiratory 
infections is clarithromycin, which we did not find to 
have stronger association with OHCA than penicillin V. 
Contrary to the present study, Svanström et al found use 
of clarithromycin to be associated with increased risk 
of cardiac death.5 They did, however, find that users of 
clarithromycin were slightly older and more likely to 
have a history of respiratory disease. Thus, clarithro-
mycin was likely to have been used for the treatment 
of asthma and COPD, which is likely to be associated to 
OHCA with or without antibiotic treatment.28 29 They 
did, however, perform a study of a national cohort and 
they list confounding by indication as a limitation for 
their study, despite of adjustment by propensity score.5
Several limitations apply to the present study. 
Although, the proarrhythmic properties of macrolide 
treatment involve prolonged cardiac repolarisation 
(ie, QT interval prolongation on an ECG) and that a 
prolonged QT interval may have preceded the OHCA, 
we are not able to prove such causation given the obser-
vational nature of the study. While the present study 
is the largest study performed to date on macrolide 
treatment and OHCA risk, the infrequency of OHCA 
as outcome of this treatment limited the final study 
cohort and may have influenced our findings. Of note, 
in neither of the studies, including our own, can we 
rule out that incorrect diagnosing can lead to OHCA 
and a misinterpreted association with use of antibiotic. 
We also acknowledge that patients in whom no resusci-
tative efforts were performed or patients with obvious 
signs of death may indeed have suffered from a cardiac 
arrest, but have been excluded from the Danish Cardiac 
Arrest Registry. Our current study holds the strength 
of enrolling members of the general population from 
a nationwide database containing all patients suffering 
from an OHCA and data on all patient usage of anti-
biotics. Unfortunately, data on specific infections, for 
which the drugs were prescribed, were not available 
for this study. Yet, we identified 514 and 1237 patients 
in treatment with a macrolide or penicillin V ≤7 days 
before the time of OHCA, respectively. Correspond-
ingly, in Denmark, the overall national use of macrolides 
(combined with lincosamides) and β-lactamase-suscep-
tible penicillins (ie, penicillin V) was approximately 2 
DDD/1000 inhabitants vs 4.4 DDD/1000 inhabitants, 
respectively.30 Another key strength is the ability to 
combine the rare outcome OHCA on a national level 
with information from national registers on hospital 
admissions, pharmacotherapy and comorbidity.
We speculate if the increased risks previously identified 
could in fact be related to the severity of infection, the 
pathogens themselves, comorbidity or incorrect diag-
noses and not necessarily the independent use of anti-
biotics. Yet, while we show no excess risk of OHCA with 
macrolide use compared with penicillin V, extrapolating 
these findings to other study populations should be done 
with caution. However, we do believe that these results can 
be applied to other similar clinical settings and macro-
lides can be prescribed when a clear medical indication is 
present and probable benefit outweighs potential risks, as 
for other antibiotics.
In conclusion, in this nationwide population-based 
study, we found comparable magnitude of association 
between overall and specific macrolide use compared 
with penicillin V and the risk of OHCA. Notably, the asso-
ciation indicated lower ORs for treatment with specific 
macrolides suggesting no causal association between 
OHCA and specific macrolides.
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